Patent intelligence · US
US 6132715
Method of inhibiting biosynthesis of tumor necrosis factor
Method of inhibiting biosynthesis of tumor necrosis factor
Patent details — US 6132715
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 17, 2000
- Expiration
- Oct 12, 2020
- Applicant
- Nika Health Products Limited
- Claims
- 10
- CPC classes
- A61K, A61K38/47, A61P, A61P29/00
Quick answer
US 6132715 (Method of inhibiting biosynthesis of tumor necrosis factor) is held by Nika Health Products Limited. Status: expired. Granted Oct 17, 2000. Expires Oct 12, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Nika Health Products Limited
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K38/47, A61P, A61P29/00, A61P31/00, A61P31/04
More from Nika Health Products Limited
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 6132715?
US 6132715 (Method of inhibiting biosynthesis of tumor necrosis factor) is held by Nika Health Products Limited. Status: expired. Granted Oct 17, 2000. Expires Oct 12, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6132715?
Nika Health Products Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 6132715 expire?
Our index shows an expiration date of Oct 12, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.